AEON Biopharma, Inc. financial data

Symbol
AEON, AEON-WT on NYSE
Industry
Pharmaceutical Preparations
Location
5 Park Plaza, Suite 1750, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Priveterra Acquisition Corp. (to 7/24/2023)
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 49.8 % +319%
Debt-to-equity -109 % -93.3%
Return On Equity 161 %
Return On Assets -2.17 K % -108229%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.1 M shares
Common Stock, Shares, Outstanding 38.1 M shares
Entity Public Float 14.2 M USD
Common Stock, Value, Issued 4 K USD
Weighted Average Number of Shares Outstanding, Basic 37.3 M shares -73.2%
Weighted Average Number of Shares Outstanding, Diluted 37.3 M shares -73.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.73 M USD -37.7%
Operating Income (Loss) -74.2 M USD -468%
Nonoperating Income (Expense) -43.9 M USD -855%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -118 M USD -569%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -118 M USD -569%
Earnings Per Share, Basic -3.17 USD/shares -2338%
Earnings Per Share, Diluted -3.17 USD/shares -2338%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.56 M USD
Assets, Current 2.5 M USD +361%
Property, Plant and Equipment, Net 307 K USD
Operating Lease, Right-of-Use Asset 198 K USD
Other Assets, Noncurrent 29 K USD
Assets 3.03 M USD -86%
Accounts Payable, Current 6.52 M USD
Employee-related Liabilities, Current 1.34 M USD
Liabilities, Current 16 M USD +172%
Operating Lease, Liability, Noncurrent 52 K USD
Liabilities 201 M USD +2436%
Retained Earnings (Accumulated Deficit) -592 M USD -7949%
Stockholders' Equity Attributable to Parent -153 M USD +46.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -198 M USD +30.8%
Liabilities and Equity 3.03 M USD -86%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.6 M USD +22.2%
Net Cash Provided by (Used in) Financing Activities 5 M USD -16.7%
Net Cash Provided by (Used in) Investing Activities 260 M USD +322898%
Common Stock, Shares Authorized 500 M shares
Common Stock, Shares, Issued 38.1 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.6 M USD +28.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.56 M USD -66.8%
Deferred Tax Assets, Valuation Allowance 54 M USD +17.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 54.1 M USD +17.3%
Operating Lease, Liability 205 K USD
Lessee, Operating Lease, Liability, to be Paid 213 K USD
Property, Plant and Equipment, Gross 502 K USD
Operating Lease, Liability, Current 205 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 292 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 213 K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8 K USD
Deferred Tax Assets, Operating Loss Carryforwards 28.6 M USD +42.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1 M shares 0%
Unrecognized Tax Benefits 14.7 M USD +32.6%
Operating Lease, Payments 80 K USD +3.9%
Additional Paid in Capital 32 K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 25 K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 153 K USD -32.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%